vs
豪洛捷（HOLX）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Rithm Capital Corp.的1.3倍（$1.0B vs $828.2M），豪洛捷净利率更高（17.1% vs 13.2%，领先3.9%），豪洛捷同比增速更快（2.5% vs -40.0%），过去两年豪洛捷的营收复合增速更高（1.5% vs -17.9%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
HOLX vs RITM — 直观对比
营收规模更大
HOLX
是对方的1.3倍
$828.2M
营收增速更快
HOLX
高出42.5%
-40.0%
净利率更高
HOLX
高出3.9%
13.2%
两年增速更快
HOLX
近两年复合增速
-17.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $828.2M |
| 净利润 | $179.1M | $109.5M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | — |
| 净利率 | 17.1% | 13.2% |
| 营收同比 | 2.5% | -40.0% |
| 净利润同比 | -10.9% | 20.9% |
| 每股收益（稀释后） | $0.79 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.0B | $768.4M | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $988.0M | $619.5M | ||
| Q2 24 | $1.0B | $1.2B |
净利润HOLXRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $179.1M | $85.0M | ||
| Q3 25 | $187.2M | $221.5M | ||
| Q2 25 | $194.9M | $311.7M | ||
| Q1 25 | $-17.4M | $78.8M | ||
| Q4 24 | $201.0M | $290.2M | ||
| Q3 24 | $178.6M | $121.7M | ||
| Q2 24 | $194.5M | $235.6M |
毛利率HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
营业利润率HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 22.6% | 13.8% | ||
| Q3 25 | 22.6% | 21.4% | ||
| Q2 25 | 24.9% | 25.2% | ||
| Q1 25 | -0.7% | 7.4% | ||
| Q4 24 | 22.5% | 23.8% | ||
| Q3 24 | 23.3% | 7.3% | ||
| Q2 24 | 24.1% | 23.6% |
净利率HOLXRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | 17.1% | 5.7% | ||
| Q3 25 | 17.8% | 20.0% | ||
| Q2 25 | 19.0% | 25.6% | ||
| Q1 25 | -1.7% | 10.3% | ||
| Q4 24 | 19.7% | 14.0% | ||
| Q3 24 | 18.1% | 19.7% | ||
| Q2 24 | 19.2% | 19.2% |
每股收益（稀释后）HOLXRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $0.79 | $0.09 | ||
| Q3 25 | $0.84 | $0.35 | ||
| Q2 25 | $0.86 | $0.53 | ||
| Q1 25 | $-0.08 | $0.07 | ||
| Q4 24 | $0.87 | $0.50 | ||
| Q3 24 | $0.75 | $0.20 | ||
| Q2 24 | $0.82 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | — |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $9.1B |
| 总资产 | $9.2B | $53.4B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $1.8B | ||
| Q3 25 | $2.2B | $1.6B | ||
| Q2 25 | $1.9B | $1.6B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.3B | $1.6B | ||
| Q2 24 | $2.4B | $1.2B |
总债务HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $35.4B | ||
| Q3 25 | $2.5B | $32.2B | ||
| Q2 25 | $2.5B | $31.2B | ||
| Q1 25 | $2.5B | $32.2B | ||
| Q4 24 | $2.5B | $32.6B | ||
| Q3 24 | $2.5B | $29.6B | ||
| Q2 24 | $2.5B | $30.1B |
股东权益HOLXRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $5.2B | $8.4B | ||
| Q3 25 | $5.0B | $8.5B | ||
| Q2 25 | $4.8B | $7.9B | ||
| Q1 25 | $4.6B | $7.8B | ||
| Q4 24 | $4.8B | $7.8B | ||
| Q3 24 | $5.1B | $7.7B | ||
| Q2 24 | $5.0B | $7.3B |
总资产HOLXRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $9.2B | $53.1B | ||
| Q3 25 | $9.0B | $47.2B | ||
| Q2 25 | $8.8B | $44.3B | ||
| Q1 25 | $8.5B | $45.3B | ||
| Q4 24 | $8.7B | $46.0B | ||
| Q3 24 | $9.2B | $42.3B | ||
| Q2 24 | $8.9B | $42.0B |
负债/权益比HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | 4.20× | ||
| Q3 25 | 0.50× | 3.79× | ||
| Q2 25 | 0.52× | 3.92× | ||
| Q1 25 | 0.55× | 4.14× | ||
| Q4 24 | 0.53× | 4.18× | ||
| Q3 24 | 0.49× | 3.87× | ||
| Q2 24 | 0.51× | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $-114.6M | ||
| Q3 25 | $355.1M | $-2.0B | ||
| Q2 25 | $343.3M | $-557.1M | ||
| Q1 25 | $169.4M | $1.4B | ||
| Q4 24 | $189.3M | $-1.8B | ||
| Q3 24 | $367.0M | $768.1M | ||
| Q2 24 | $405.8M | $-55.7M |
自由现金流HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — |
自由现金流率HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — |
资本支出强度HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — |
现金转化率HOLXRITM
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | -1.35× | ||
| Q3 25 | 1.90× | -9.22× | ||
| Q2 25 | 1.76× | -1.79× | ||
| Q1 25 | — | 18.03× | ||
| Q4 24 | 0.94× | -6.04× | ||
| Q3 24 | 2.05× | 6.31× | ||
| Q2 24 | 2.09× | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
